4.370
-0.050
(-1.13%)
At close: 4:08:06 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
517,458
441,126
250,833
136,534
38,655
Cost of Revenue
146,180
115,756
74,632
40,880
13,432
Gross Profit
371,278
325,370
176,201
95,654
25,223
Operating Expense
642,283
741,198
727,925
645,256
234,488
Operating Income
-271,005
-415,828
-551,724
-549,602
-209,265
Net Non Operating Interest Income Expense
33,720
39,259
44,313
24,585
37,211
Pretax Income
-248,507
-391,501
-398,235
-574,216
-2,068,656
Tax Provision
3,254
1,052
9,574
--
--
Net Income Common Stockholders
-251,737
-392,525
-407,809
-574,216
-2,068,656
Diluted NI Available to Com Stockholders
-251,737
-392,525
-407,809
-574,216
-2,068,656
Basic EPS
-0.37
-0.58
-0.61
-0.86
-4.43
Diluted EPS
-0.37
-0.58
-0.61
-0.86
-4.43
Basic Average Shares
680,255.500
679,275
673,160
661,656
466,994
Diluted Average Shares
680,255.500
679,275
673,160
661,656
466,994
Total Operating Income as Reported
-282,227
-430,760
-442,548
-598,801
-403,717
Total Expenses
788,463
856,954
802,557
686,136
247,920
Net Income from Continuing & Discontinued Operation
-251,737
-392,525
-407,809
-574,216
-2,068,656
Normalized Income
-251,195.500
-374,864
-395,231.500
-574,678
-392,751
Interest Income
33,899
39,437
46,629
24,771
37,302
Interest Expense
179
178
2,316
186
91
Net Interest Income
33,720
39,259
44,313
24,585
37,211
EBIT
-248,328
-391,323
-395,919
-574,030
-2,068,565
EBITDA
-248,328
-348,521
-359,905
-546,544
-2,049,087
Reconciled Cost of Revenue
146,180
115,756
74,632
40,880
13,432
Reconciled Depreciation
--
42,802
36,014
27,486
19,478
Net Income from Continuing Operation Net Minority Interest
-251,737
-392,525
-407,809
-574,216
-2,068,656
Total Unusual Items Excluding Goodwill
-722
-23,548
-16,770
462
-1,675,905
Total Unusual Items
-722
-23,548
-16,770
462
-1,675,905
Normalized EBITDA
-247,606
-324,973
-343,135
-547,006
-373,182
Tax Rate for Calcs
0
0
0
--
--
Tax Effect of Unusual Items
-180.500
-5,887
-4,192.500
--
--
12/31/2020 - 5/15/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6609.HK Shanghai HeartCare Medical Technology Corporation Limited
27.000
-0.74%
2500.HK Venus Medtech (Hangzhou) Inc.
2.050
+5.67%
OSL.AX OncoSil Medical Limited
0.0040
0.00%
0853.HK MICROPORT
6.600
-1.05%
EW Edwards Lifesciences Corporation
67.52
+0.67%
BSX Boston Scientific Corporation
88.59
-2.26%
TMDX TransMedics Group, Inc.
70.09
+3.14%
DXCM DexCom, Inc.
61.44
+1.24%
MDT Medtronic plc
81.09
-0.97%
ABT Abbott Laboratories
122.59
-1.10%